摘要
目的探讨通心络胶囊对冠心病患者血清炎症因子以及颈动脉粥样斑块的影响。方法将56例冠心病患者随机均分为通心络治疗组(A组)及常规治疗组(B组)。B组给予常规治疗;A组在常规治疗基础上加用通心络胶囊口服,每次3颗,每日3次,6个月后观察两组患者血清内脏脂肪因子(visfatin)和IL-6以及颈动脉内-中膜厚度(IMT)、颈动脉粥样斑块面积的变化。结果与B组比较,A组治疗6个月后的visfatin和IL-6浓度下降明显[(10.20±0.70)ng/L vs.(9.60±0.77)ng/L和(9.45±0.69)pg/L vs.(9.03±0.81)pg/L](P<0.05)。A组IMT及颈动脉粥样斑块的面积在用药后有降低和减小的趋势,但与B组比较,差异无统计学意义(P>0.05)。结论通心络胶囊可抑制冠心病患者血清visfatin和IL-6的表达,但对颈动脉IMT及颈动脉粥样斑块面积影响不明显。
Objective To study the effects of Tongxinluo capsule on inflammatory markers and carotid arterial plaque in the patients with coronary artery disease （CAD）. Methods FiftyLsix CAD patients were equally randomized into groups of B（treated with conventional therapy） and A（treated with additional oral Tongxinluo capsule 3 pills three times per day for 6 months）. Serum visfatin and interleukin-6（IL-6） were detected and intima-media thickness（IMT） and plaque areas were observed before and after treatment. Results Serum levels of visfatin and IL-6 after 6-month treatment were lower in group A than those in group B[（9. 60±0. 77） ng/L vs. （10.20±0. 70） ng/L and （9.03± 0. 81） pg/L vs, （9.45±0, 69） pg/L]（P〈0, 05）, A tendency of reduced IMT and plaque areas was seen after 6-month treatment, but the changes were not significantly different from those in group B （P〈0. 05）. Conclusion Additional treatment with Tongxinluo capsule may effectively inhibit the expressions of visfatin and IL-6, but has no significant effects on carotid IMT and plaque areas in the natients with CAD.
出处
《江苏医药》
CAS
CSCD
北大核心
2012年第8期904-906,共3页
Jiangsu Medical Journal
基金
江苏省中医药局科技项目(LZ09009)
